Table 3 End of treatment and best overall response rate
Variable | CLL (n = 12) | DLBCL (n = 23) | FL (n = 13) | Overall (n = 48) | ||||
|---|---|---|---|---|---|---|---|---|
EoT response | Best overall response | EoT response | Best overall response | EoT response | Best overall response | EoT response | Best overall response | |
Responders, n (%) | 7 (58.3) | 9 (75.0) | 3 (13.0) | 6 (26.1) | 6 (46.2) | 8 (61.5) | 16 (33.3) | 23 (47.9) |
Non-responders, n (%) | 5 (41.7) | 3 (25.0) | 20 (87.0) | 17 (73.9) | 7 (53.8) | 5 (38.5) | 32 (66.7) | 25 (52.1) |
95% CI for response rate | 27.67–84.83 | 42.81–94.51 | 2.78–33.59 | 10.23–48.41 | 19.22–74.87 | 31.58–86.14 | 20.40–48.41 | 33.29–62.81 |
CR, n | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
95% CI | 0.00–26.46 | 0.00–26.46 | 0.00–14.82 | 0.00–14.82 | 0.00–24.71 | 0.00–24.71 | 0.00–7.40 | 0.00–7.40 |
CRi, n | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
95% CI | 0.00–26.46 | 0.00–26.46 | 0.00–14.82 | 0.00–14.82 | 0.00–24.71 | 0.00–24.71 | 0.00–7.40 | 0.00–7.40 |
CRu, n (%) | 0 | 0 | 1 (4.3) | 1 (4.3) | 0 | 0 | 1 (2.1) | 1 (2.1) |
95% CI | 0.00–26.46 | 0.00–26.46 | 0.11–21.95 | 0.11–21.95 | 0.00–24.71 | 0.00–24.71 | 0.05–11.07 | 0.05–11.07 |
PR, n (%) | 7 (58.3) | 9 (75.0) | 2 (8.7) | 5 (21.7) | 6 (46.2) | 8 (61.5) | 15 (31.3) | 22 (45.8) |
95% CI | 27.67–84.83 | 42.81–94.51 | 1.07–28.04 | 7.46–43.70 | 19.22–74.87 | 31.58–86.14 | 18.66–46.25 | 31.37–60.83 |
SD, n (%) | 1 (8.3) | 1 (8.3) | 2 (8.7) | 6 (26.1) | 4 (30.8) | 4 (30.8) | 7 (14.6) | 11 (22.9) |
95% CI | 0.21–38.48 | 0.21–38.48 | 1.07–28.04 | 10.23–48.41 | 9.09–61.43 | 9.09–61.43 | 6.07–27.76 | 12.03–37.31 |
PD, n (%) | 2 (16.7) | 0 | 15 (65.2) | 9 (39.1) | 3 (23.1) | 1 (7.7) | 20 (41.7) | 10 (20.8) |
95% CI | 2.09–48.41 | 0.00–26.46 | 42.73–83.62 | 19.71–61.46 | 5.04–53.81 | 0.19–36.03 | 27.61–56.79 | 10.47–34.99 |
Missing or non-evaluable, n (%) | 2 (16.7) | 2 (16.7) | 3 (13.0) | 2 (8.7) | 0 | 0 | 5 (10.4) | 4 (8.3) |